C12Y 304/2206
Caspase-7
Official title: Caspase-7 (3.4.22.60)
C12Y304/2206 (Caspase-7) appears on 4 US grants and 7 published applications in this corpus.
Search patents in C12Y- Granted patents
- 4
- Published applications
- 7
- Assignees
- 5
- Inventors
- 14
- Latest grant
- 5 Dec 2023
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 2005 | 0 | 1 |
| 2006 | 0 | 0 |
| 2007 | 0 | 1 |
| 2008 | 0 | 0 |
| 2009 | 0 | 0 |
| 2010 | 0 | 0 |
| 2011 | 0 | 0 |
| 2012 | 0 | 0 |
| 2013 | 0 | 0 |
| 2014 | 0 | 1 |
| 2015 | 2 | 1 |
| 2016 | 0 | 0 |
| 2017 | 0 | 1 |
| 2018 | 0 | 0 |
| 2019 | 1 | 1 |
| 2020 | 0 | 0 |
| 2021 | 0 | 1 |
| 2022 | 0 | 0 |
| 2023 | 1 | 0 |
By publication year.
Recent patents
- Process for determining enzyme activity in a cell by activity-based reporter gene technology (ABRGT)5 Dec 2023US 11,834,698 B2Indian Institute of Science Education and Research
- Genetically encoded infrared fluorescent protease reporters12 Feb 2019US 10,201,282 B2The Regents of the University of California
- Method for the determination of botulinum neurotoxin biological activity15 Dec 2015US 9,212,355 B2MERZ PHARMA GmbH & CO. KGaA
- Method for the determination of botulinum neurotoxin biological activity4 Aug 2015US 9,096,886 B2MERZ PHARMA GmbH & CO. KGaA
- Enhanced CAR Tregs and Bi-Specific Antibodies for Induction of Immune Tolerance, Treating Autoimmune Diseases and Preventing Transplantation Rejection2 Sep 2021US 2021/0268023 A1The Trustees of Columbia University in the City of New York
- Process for determining enzyme activity in a cell by activity-based reporter gene technology (abrgt)7 Nov 2019US 2019/0338373 A1Indian Institute of Science Education and Research
- Genetically encoded infrared fluorescent protease reporters6 Jul 2017US 2017/0188835 A1The Regents of the University of California
- Method for the determination of botulinum neurotoxin biological activity8 Oct 2015US 2015/0284702 A1MERZ PHARMA GmbH & CO. KGaA
- Method for the determination of botulinum neurotoxin biological activity2 Jan 2014US 2014/0004541 A1MERZ PHARMA GmbH & CO. KGaA
Most cited
By later US patents